Rimonabant Acomplia News
The result of recent research confirmed that Rimonabant
reduces dangerous Abdominal Obesity
At the annual meeting of the European Atherosclerosis
Society held in Instanbul was presented the result
of the ADAGIO-LIPIDS clinical trail, a study conducted
in 799 patients with abdominal obesity and with the
high triglyceride - low HDL cholesterol dyslipidemia
(condition that contributes to the develepment of
atherosclerosis known as hardening of the arteries).
In the report is said that Cat scans of obese patients
treated with Riomonabant confirmed that this drug
significantly reduces the dangerous type od abdominal
obesity that often leads to type 2 diabetes (according
to researchers).
The purpose of the study was to determine the effect
of rimonabant on HDL (good) cholesterol and trygliceride
levels and on cardiometabolic profile of overweight
and obese patients with dyslipidemia.
In this rimonabant trail, patients were given cat
svans to measure how much much subcutaneous and visceral
fat was lost on rimonabant as well as to determine
whether rimonabant could reduce liver fat.
Dr Jean-Pierre Després of Université
Laval in Quebec City, lead researcher said: "Although
we had evidence from the phase III studies conducted
with rimonabant that (the drug) could induce a reduction
in waist circumference (a crude marker of abdominal
fat) and improve several features of the metabolic
syndrome, no study had ever quantified the effect
of this drug on visceral adiposity and liver fat."
The researchers reported that rimonabant therapy
for a year reduced a "significant decrease in
the fatty liver index".
The researchers concluded: "Results of ADAGIO-LIPIDS
provide support to the notion that patients with visceral
obesity who are often either dyslipidemic or with
type 2 diabetes (or both) represent a relevant subpopulation
of overweight/obese patients who would particularly
benefit from rimonabant therapy,"
|
